Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
84.51
-1.08 (-1.26%)
May 14, 2026, 10:52 AM EDT - Market open
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $34.37M in the quarter ending March 31, 2026, with 55.50% growth. This brings the company's revenue in the last twelve months to $51.48M, down -12.58% year-over-year. In the year 2025, Kymera Therapeutics had annual revenue of $39.21M, down -16.70%.
Revenue (ttm)
$51.48M
Revenue Growth
-12.58%
P/S Ratio
136.77
Revenue / Employee
$203,462
Employees
253
Market Cap
6.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.21M | -7.86M | -16.70% |
| Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
| Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
| Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
| Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
| Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
| Dec 31, 2019 | 2.93M | - | - |
| Dec 31, 2018 | 2.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.51B |
| Bio-Techne | 1.21B |
| PTC Therapeutics | 827.11M |
| TG Therapeutics | 700.35M |
| Mirum Pharmaceuticals | 569.61M |
| Protagonist Therapeutics | 74.06M |
| Centessa Pharmaceuticals | 15.00M |
| CG Oncology | 5.07M |
KYMR News
- 1 day ago - Kymera Therapeutics Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 7 days ago - Kymera Therapeutics initiated with a Buy at Canaccord - TheFly
- 7 days ago - Kymera Therapeutics initiated with a Buy at Canaccord - TheFly
- 8 days ago - Kymera Therapeutics to Participate in Upcoming May Investor Conferences - GlobeNewsWire
- 9 days ago - Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week - GlobeNewsWire
- 13 days ago - Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley - TheFly
- 14 days ago - Kymera Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 14 days ago - Kymera Therapeutics reports Q1 EPS (71c), consensus (86c) - TheFly